Thickness of GCIPL, INL of Retina Reduced in Parkinson Disease
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 24, 2023 -- Reduced thickness of the ganglion cell-inner plexiform layer (GCIPL) and inner nuclear layer (INL) of the retina are seen in individuals with Parkinson disease (PD), according to a study published online Aug. 21 in Neurology.
Siegfried Karl Wagner, M.D., from the University College London, and colleagues used data from a retrospective cohort of 154,830 patients aged 40 years and older from the AlzEye cohort to detect retinal markers, measured using optical coherence tomography, in prevalent PD from 2008 to 2018. In addition, retinal markers were examined in incident PD using data from 67,311 volunteers aged 40 to 69 years from the U.K. Biobank who underwent retinal imaging during 2006 to 2010.
The researchers identified 700 patients with prevalent PD and 105,770 controls within the AlzEye cohort. Thinner GCIPL and INL were seen for individuals with prevalent PD (–2.12 and –0.99 µm, respectively). Fifty-three participants from the U.K. Biobank developed PD at a mean of 2,653 ± 851 days. Associations were seen for thinner GCIPL and thinner INL with incident PD (hazard ratios, 0.62 per standard deviation increase and 0.70, respectively).
"I continue to be amazed by what we can discover through eye scans. While we are not yet ready to predict whether an individual will develop Parkinson's, we hope that this method could soon become a pre-screening tool for people at risk of disease," Wagner said in a statement.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.